-
Results from a just-published study indicate that teens who are treated for pelvic inflammatory disease (PID) are at risk for subsequent sexually transmitted infections (STIs) and/or PID for 48 months.1 What can clinicians do to stem subsequent infection?
-
Good news: About 75% of respondents to the 2008 Contraceptive Technology Update Salary Survey say they received increases in their paychecks in the last year. Bad news: The majority (57%) saw only a 1%-3% increase.
-
Results from a Phase III study in men ages 16 to 26 indicate that the human papillomavirus (HPV) vaccine Gardasil (Merck & Co.) prevented 90% of external genital lesions caused by types 6, 11, 16, and 18 of HPV.
-
How many of your patients rely on vasectomy for contraception? About 500,000 vasectomies are performed each year in the United States; about one out of six U.S. men over age 35 has been vasectomized, with prevalence increasing with education and income.
-
Two years after the government implemented routine HIV testing for all patients ages 13-64 without regard to risk, public health officials say improvements have been made, yet still one in five people infected with the AIDS virus is unaware of his/her status.
-
White coat hypertension and Type 2 diabetes; Vitamin K and insulin resistance; Aspirin for all? Not so fast; Non-fasting triglycerides and risk of stroke; ACE/CCB or ACE/HCTZ for HTN: Which is better?; Putting sunscreen to the test
-
In a longitudinal population-based study, metformin use was associated with an increased incidence of low thyroid-stimulating hormone (TSH) levels in patients with treated hypothyroidism.
-
Polycystic ovarian syndrome patients with normospermic partners undergoing ovulation induction with letrozole had a higher live birth rate and no increase in adverse outcomes than women who received clomiphene citrate.
-
According to this pharmacokinetic study, the cyclic use of 20 mcg ethinyl estradiol oral contraceptives is problematic for obese women. Ovarian activity was better suppressed with continuous use (omitting the hormone-free interval) of the same dose oral contraceptive or increasing to a higher dose 30 mcg ethinyl estradiol oral contraceptive
-
A large prospective cohort study of perineal talc use demonstrated no increased risk of ovarian cancer overall or within any histological subtype. In addition, no association with talc application method was observed.
